{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:04:00Z","timestamp":1769069040813,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.yebeh.2013.09.041","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T05:15:25Z","timestamp":1383801325000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Concomitant therapy in people with epilepsy: Potential drug\u2013drug interactions and patient awareness"],"prefix":"10.1016","volume":"31","author":[{"given":"Sara","family":"Eyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivan","family":"Rasaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Ekstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2013.09.041_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":"Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population","volume":"95","author":"Johannessen-Landmark","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.seizure.2007.02.006","article-title":"Clinical use of antiepileptic drugs at a referral centre for epilepsy","volume":"16","author":"Johannessen-Landmark","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993\u20132008: cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-0404.2006.00639.x","article-title":"Trends in utilization of antiepileptic drugs in Denmark","volume":"113","author":"Tsiropoulos","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0025","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1528-1167.2009.02512.x","article-title":"Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy","volume":"51","author":"Alexandre","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/01.wnl.0000341789.77291.8d","article-title":"Assessment of potential drug interactions in patients with epilepsy: impact of age and sex","volume":"72","author":"Gidal","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0035","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1528-1157.1998.tb01294.x","article-title":"Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use","volume":"39","author":"Lackner","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2010.08.002","article-title":"Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy","volume":"91","author":"Malerba","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0045","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/j.1528-1167.2009.02090.x","article-title":"Understanding herb and dietary supplement use in patients with epilepsy","volume":"50","author":"Kaiboriboon","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2004.10.007","article-title":"The use of complementary medicines and alternative practitioners in a cohort of patients with epilepsy","volume":"6","author":"Easterford","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/ebeh.2000.0031","article-title":"Alternative medicine use by patients with epilepsy","volume":"1","author":"Peebles","year":"2000","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0060","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1212\/01.WNL.0000073541.08356.47","article-title":"Complementary\/alternative medicine for epilepsy in Arizona","volume":"61","author":"Sirven","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0070","series-title":"Drug interactions analysis and management","author":"Hansten","year":"2012"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0075","series-title":"DRUG-REAX system","author":"Micromedex\u00ae","year":"2012"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0080","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/ph3051426","article-title":"Natural products in epilepsy\u2014the present situation and perspectives for the future","volume":"3","author":"Ekstein","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1331\/154434504773062591","article-title":"Identification of serious drug\u2013drug interactions: results of the partnership to prevent drug\u2013drug interactions","volume":"44","author":"Malone","year":"2004","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0100","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.yebeh.2009.01.024","article-title":"Antiepileptic drugs: are women aware of interactions with oral contraceptives and potential teratogenicity?","volume":"14","author":"Pack","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.1995.03530010049034","article-title":"Systems analysis of adverse drug events. ADE Prevention Study Group","volume":"274","author":"Leape","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group","volume":"277","author":"Bates","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0125","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1212\/01.wnl.0000313157.15089.e6","article-title":"Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000\u20132004","volume":"70","author":"Pugh","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.seizure.2009.05.011","article-title":"Antiepileptic drug treatment of children at a referral centre for epilepsy\u2014does admission make a difference?","volume":"18","author":"Rytter","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0140","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00228-003-0700-5","article-title":"Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid","volume":"59","author":"Ucar","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.75.884.359","article-title":"Efficacy of statin therapy: possible effect of phenytoin","volume":"75","author":"Murphy","year":"1999","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0150","doi-asserted-by":"crossref","first-page":"H704","DOI":"10.1152\/ajpheart.00580.2001","article-title":"Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults","volume":"282","author":"Br\u00e4mswig","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0155","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0009-9120(97)00116-1","article-title":"Homocyst(e)ine levels in patients on phenytoin therapy","volume":"30","author":"James","year":"1997","journal-title":"Clin Biochem"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0160","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/01.STR.0000125863.93921.3f","article-title":"Favorable outcome of ischemic stroke in patients pretreated with statins","volume":"35","author":"Mart\u00ed-F\u00e0bregas","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0165","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1161\/STROKEAHA.108.546259","article-title":"Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS)","volume":"40","author":"Leker","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1528-1167.2012.03693.x","article-title":"Comparative stroke risk of antiepileptic drugs in patients with epilepsy","volume":"54","author":"Hsieh","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0404.2004.00324.x","article-title":"The psychiatric comorbidity of epilepsy","volume":"110","author":"Gaitatzis","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0180","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrneurol.2011.104","article-title":"Depression in epilepsy: a critical review from a clinical perspective","volume":"7","author":"Hoppe","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0185","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1528-1167.2011.03276.x","article-title":"International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy","volume":"52","author":"Kerr","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0190","series-title":"Goodman & Gilman's the pharmacological basis of therapeutics","first-page":"1787","article-title":"Design and optimization of dosage regimens: pharmacokinetic data","author":"Thummel","year":"2006"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.seizure.2007.11.020","article-title":"Bone health in people with epilepsy: is it impaired and what are the risk factors?","volume":"17","author":"Pack","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0200","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/75.9.933","article-title":"Drug\u2013grapefruit juice interactions","volume":"75","author":"Kane","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0205","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0009-9236(98)90177-1","article-title":"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy","volume":"64","author":"Garg","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0210","series-title":"Product information: Tegretol, Tegretol XR","year":"2011"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0215","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.seizure.2006.02.002","article-title":"Antiepileptic drug use in nursing home residents: a cross-sectional, regional study","volume":"15","author":"Huying","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0220","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1474-4422(12)70103-5","article-title":"Teratogenic effects of antiepileptic drugs","volume":"11","author":"Tomson","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0230","first-page":"1081","article-title":"Patient education and oral anticoagulant therapy","volume":"87","author":"Barcellona","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1345\/aph.1A198","article-title":"Relationship between patients' warfarin knowledge and anticoagulation control","volume":"37","author":"Tang","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2013.09.041_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2318-8-13","article-title":"Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review","volume":"8","author":"Verhovsek","year":"2008","journal-title":"BMC Geriatr"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505013005076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505013005076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:55:00Z","timestamp":1539219300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505013005076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":48,"alternative-id":["S1525505013005076"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2013.09.041","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant therapy in people with epilepsy: Potential drug\u2013drug interactions and patient awareness","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2013.09.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}